Consistent with this, reanalysis of the TCGA PRAD cohort (n = 497) showed that tumor T-stage progression was associated with SRD5A1 and HSD17B3 gene amplification and gain, but shallow or deep deletion of SHBG and HSD17B2 genes (Figure 1D). This evidence concerns the gene HSD17B3 and prostate adenocarcinoma.